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Background:  The  incidence  of  cytomegalovirus  (CMV)  syndrome/disease  after  adult  solid  organ  trans-
plantation  in  the  era  effective  antiviral  therapy  has not  been  fully  assessed.
Objective:  To  determines  the  incidence  of CMV  syndrome/disease  after  solid  organ  transplantation  in the
UK.
Study design:  A retrospective  analysis  of 1807  solid  organ  transplants  from  12  UK  solid  organ  trans-
plant  centres  representing  32.7%  of  all  transplant  activity  occurring  in the  UK  between  1/04/2004  and
31/03/2006.  Patients  were  categorised  into  those  experiencing  an episode  of  symptomatic  CMV  infection
after  transplant  or those  who  remained  free  of  symptoms.  All  patients  were  followed  up for  2 years  for
the occurrence  of CMV  syndrome/disease.
Results:  The  majority  of  the  transplant  centres  used  valganciclovir  prophylaxis  in  the  high  risk  D+R−
patients  (91.6%)  whereas  management  of  the  lower  risk  D+R+  and D−R+ patients  was  more  variable  with
deployment  of both  prophylactic  and  pre-emptive  strategies  in  ∼50%  of  centres.  CMV  syndrome/disease
occurred  in  20.5%  of  the  D+R−  patients  representing  55  cases  whereas  the  incidence  was  only  8.1% and
9%  in  the  D+R+ and  D−R+ group,  respectively  (p  <  0.001  compared  to  the  D+R−  group),  but  representing  a
further  58  cases  of CMV  syndrome/disease.  CMV  viraemia  in the  D+R−  group  was  associated  with a  high
probability  (65%)  of  CMV  syndrome/disease  in  renal  transplant  recipients  whereas  this  was  less  apparent
in the  intermediate  risk  groups.
Conclusions:  CMV  syndrome/disease  remains  an important  healthcare  burden  after  solid  organ  transplan-
tation  with  the  intermediate  risk  groups  contributing  similar  numbers  of  cases  as  the  high risk  group.. Background
Historically cytomegalovirus (CMV) disease was  associated with
 high morbidity and mortality after solid organ transplantation.1
n recent years, the combination of improved antiviral manage-
ent and immunosuppressive strategies has minimised the health
mpact of CMV  in this clinical setting.2–6 Despite the widespread
eployment of antiviral prophylaxis for high-risk patients reduc-
ng the risk of infection and disease during the prophylaxis period
ate infection and disease remain important clinical management
hallenges.7–10 In addition, the appropriate antiviral manage-
ent (prophylaxis or pre-emptive antiviral therapy) of patients
Abbreviations: CMV, cytomegalovirus; D, donor; R, recipient.
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at intermediate risk of infection and disease remains controver-
sial even though these patients represent a sizeable transplanted
population.11
While clinical trials provide essential benchmarks for drug efﬁ-
cacy there remains an important place for information gathered
from audits across multiple centres to inform healthcare managers
and physicians on the current impact that CMV  has following solid
organ transplantation.
2. Objectives
To assess the incidence of CMV  syndrome/disease after solid
organ transplantation especially in the recipient CMV  seropositive
population.
Open access under CC BY license.3. Study design
The survey was a retrospective analysis of centres that trans-
planted solid organs within the UK between 1/04/2004 and
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Table 1
Distribution of patients across the 9 participating UK centres.
Hospital ID Kidney Liver Pancreas Heart Lung
A 155 112 13a
B 93 94 26b
C 70 51c
D 67
E 159 28d
F 216 244
G  99
H 313
I 32 35
Total 1035 517 67 102 86
a All simultaneous kidney-pancreas (SKP).
b 23 SKP + 3 pancreas only.26 V.C. Emery et al. / Journal of C
1/03/2006. Patients were categorised into either those who devel-
ped an episode of symptomatic CMV  infection after transplant or
hose who remained free of symptoms related to CMV. All patients
ere stratiﬁed according to their risk of CMV  infection based upon
onor and recipient CMV  serology. Patients were followed up for 2
ears for the occurrence of CMV  syndrome/disease (deﬁned below).
owever, patients were excluded from the ﬁnal analysis if their care
ransferred to another centre within 2 years of follow-up.
.1. Primary objective
The primary objective of the study was to characterise the
requency of symptomatic CMV  infection after solid organ trans-
lantation in the UK setting.
.2. Inclusion/exclusion criteria
Patients who received a solid organ transplant within the UK
etween 1/04/2004 and 31/03/2006. There were no exclusion crite-
ia.
.3. Participating centres
All UK hospitals performing adult heart, lung and liver trans-
lantation were approached to participate in the study along with
 centres performing kidney transplantation only. This represented
1 of 36 adult transplanting units. Nine hospitals representing
2 transplant units participated in the study. Information on the
ntiviral CMV  management strategy in place during the study
eriod was collected from each centre. The study was  conducted
n accordance with good clinical practice (GCP) guidelines.
.4. CMV  disease deﬁnitions
CMV  syndrome was deﬁned as CMV  PCR (polymerase chain
eaction) viraemia plus fever of unexplained origin and one of the
ollowing signs: leucopenia, myalgia or arthralgia.11
CMV  disease was deﬁned according to the Ljungman et al.:12
1) Detection of CMV  by culture, histopathology, immunohisto-
chemistry with CMV  speciﬁc antibodies or in situ hybridisation
in a biopsy of the affected organ.
2) CMV  central nervous system (CNS) disease could be diagnosed
by the presence of CMV  DNA or virus culture positivity in the
cerebrospinal ﬂuid.
3) CMV  retinitis diagnosed by qualiﬁed ophthalmologist.
4) CMV  hepatitis diagnosed by the presence of CMV  in a liver
biopsy by histology (CMV inclusions or immunohistochem-
istry).
5) CMV  colitis diagnosed by the presence of CMV  in a gut biopsy
by histology (CMV inclusions or immunohistochemistry).
Patients experiencing CMV  viraemia without disease were clas-
iﬁed as having asymptomatic viraemia. No data on viral load for
MV  were obtained as part of the audit. In centres adopting pre-
mptive therapy, CMV  surveillance was undertaken by real time
CR methods (either commercial or in-house on plasma or whole
lood) on a weekly basis until 3-months post transplant. Consistent
ost prophylaxis surveillance was not routinely adopted. Thresh-
lds for initiation of therapy varied between centres but ﬁrst-line
herapy involved either intravenous ganciclovir (5 mg/kg bid) or
alganciclovir (900 mg  bid) and was adjusted for renal function.c 6 heart/lung + 11 single lung + 34 bi-lateral lung.
d 26 SKP + 2 pancreas only.
3.5. Statistical analysis
Comparison of incidence between groups was  performed using
the chi-squared test or Fisher’s exact test as appropriate. p-values
≤0.05 were regarded as signiﬁcant.
4. Results
Nine hospitals participated in the study performing 1807 solid
organ transplants during the 2-year study period. The majority
were renal transplant recipients (57.3%) with the next largest popu-
lation being liver transplant recipients (28.6%). The total number of
solid organ transplants carried out in the UK during the study period
was 5518 (UK Transplant Registry data) and so the participating
centres in our study represented 32.7% of all transplant activity
occurring in the UK during the 2 year period from 2004 to 2006.
The distribution of transplants amongst the 9 hospitals is shown in
Table 1.
The individual antiviral management strategies adopted for
each solid organ transplant group stratiﬁed according to the donor
and recipient serostatus for CMV  is shown in Table 2. In the high-
risk D+R− group the majority of CMV  protocols deployed antiviral
prophylaxis with valganciclovir (VGCV) at 900 mg  once a day for
90 days (76.4%) with the remaining protocols used a lower dose
of VGCV (450 mg  od for 90 days) and one heart transplant proto-
col deployed no prophylaxis or pre-emptive therapy in this high
risk group. In the intermediate risk D+R+ group, a more diverse
range of management strategies were deployed with 47% of cen-
tres performing neither prophylaxis nor pre-emptive therapy, 35%
performing prophylaxis with VGCV at either 900 mg once daily or
450 mg  once daily for 90 days and 17% performing pre-emptive
therapy with valganciclovir at full dose. In the low risk category
(D−R+), the majority of transplant units (53%) were performing
neither prophylaxis nor pre-emptive therapy. With a single excep-
tion, the remaining centres followed a management strategy for the
D−R+ patients that was  the same as for the D+R+ group. For patients
with virtually no risk of CMV  infection and disease after transplan-
tation (donor and recipient both seronegative, D−R−), the majority
of CMV  protocols (82.3%) undertook no antiviral prophylaxis or pre-
emptive therapy. However, 3 centres adopted pre-emptive therapy
for these low risk patients.
The incidence of CMV  disease in the different patient popula-
tions who  had achieved 2 years of follow-up stratiﬁed according
to donor and recipient seropositivity is shown in Table 3. CMV
disease continues to be most prevalent in the high risk D+R− set-
ting (despite the fact that majority of these patients were receiving
prophylaxis) with an average rate of 20.5%. The rate was reduced
signiﬁcantly in the D+R+ group (8.1%; p < 0.001 vs D+R−) but it
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Table 2
CMV antiviral management strategies deployed in different solid organ transplant recipients stratiﬁed according to CMV  donor and recipient serostatus.
Organ Number of centres D+R− D+R+ D−R+ D−R−
Kidney 3 VGCV 900 mg  90 d None None None
2  VGCV 900 mg  90 d PET PET PET
1 VGCV 900 mg  90 d VGCV 900 mg 90 da VGCV 900 mg 90 da None
Liver  3 VGCV 900 mg  90 d None None None
1 VGCV 900 mg  90 d VGCV 900 mg 90 d None None
SPK/Pancreas 1 VGCV 450 mg 90 d VGCV 900 mg 90 d VGCV 900 mg 90 d None
1  VGCV 900 mg  90 d PET PET PET
1  VGCV 900 mg  90 d VGCV 900 mg 90 d VGCV 900 mg 90 d None
Heart 1 VGCV 450 mg 90 d VGCV 450 mg  90 d VGCV 450 mg  90 d None
1 None None None None
Lung  1 VGCV 450 mg 90 d VGCV 450 mg  90 d VGCV 450 mg  90 d None
1  VGCV 900 mg  90 d None None None
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Key: SPK = simultaneous pancreas and kidney and (includes 1 pancreas only transp
ET  = pre-emptive therapy; 90 d = 90 days
a Only if patient has received Campath therapy.
as noteworthy that the prevalence in the lung transplant recipi-
nts was comparable to that observed in the high-risk population.
he D+R+ renal transplant recipients had a 40% reduction in their
ncidence of CMV  disease compared to the D+R− group. In the
−R+ group, the average incidence of CMV  disease was  lower than
hat observed in the D+R− group (mean 9.0%; p < 0.001) and com-
arable to that observed in the D+R+ group although the high
ncidence of disease in both lung and heart transplant recipients
hould be noted. Overall the number of patients with CMV  syn-
rome/disease in the recipient seropositive group was  comparable
o the number of cases of syndrome/disease in the D+R− group
58 cases in the R+ group vs 55 cases in the D+R− group; p = not
igniﬁcant). The incidence of overt CMV  disease in the D−R−
roup was very low (0.1%) equating to a single liver transplant
ecipient.
In the context of CMV  viraemia and its association with the
ccurrence of CMV  syndrome and disease, data were available for
 renal transplant centres and 3 liver transplant centres represent-
ng a total of 1547 patients (85.6% of the total patient evaluable).
hese data are summarised in Tables 4 and 5, respectively. In the
+R− renal transplant recipients the overall rate of CMV viraemia
as 36.2% with the rate of asymtomatic CMV  viraemia relatively
ow at 12.1% whereas CMV  syndrome with concurrent viraemia
as recorded at a higher level (22.4%) and overt CMV  disease only
bserved in one patient. In contrast, both the D+R+ and the D−R+
enal transplant groups exhibited higher levels of asymptomatic
MV  viraemia (24.1% and 32.8%, respectively) compared to the
+R− group although the incidence of CMV  syndrome was  sig-
iﬁcantly lower in both groups compared to the high risk group
p = 0.026 for D+R+ and p = 0.0012 for the D−R+ comparison). In
atients where both donor and recipient were seronegative the
ncidence of asymptomatic viraemia and syndrome were extremely
ow (Table 4).
able 3
ncidence of CMV  disease (including syndrome) in different organ transplant recipients a
ollow-up data, who  lost their graft or died during the 2 year period.
D+R− D+R+ D−R
Transplant group N CMV  disease (%) N CMV  disease (%) N 
Renal 143 21.5 203 12.8 144 
Liver  73 20.5 141 5.7 142 
SPK  12 25.0 1 0.0 11 
Heart 33 6.1 16 0.0 22 
Lung(s) 17 29.4 18 22.2 26 
Totals 278 20.5 379 8.1 345 
ey: SPK = simultaneous pancreas and kidney and (includes 1 pancreas only transplant).VGCV = valganciclovir; 900 mg = daily prophylactic dose for normal renal function;
In a similar analysis of liver transplant recipients, the over-
all incidence of asymptomatic CMV  viraemia was  lower than that
observed across all donor–recipient CMV  groups after renal trans-
plantation although it only reached statistical signiﬁcance for the
D−R+ comparison (p = 0.003). Consistent with the data in the high
risk D+R− renal transplant group there was  a lower rate of asymp-
tomatic CMV  viraemia (7.7%) compared to the occurrence of CMV
syndrome/disease (21.3%). This effect was not observed in the
other donor/recipient groups where the incidence of asymptomatic
viraemia was  always greater than CMV  syndrome/disease (Table 5).
We next investigated whether the management strategy
adopted in the lower risk (D+R+ and D−R+) settings was associated
with differences in CMV  syndrome/disease incidence. In seropos-
itive renal transplant recipients receiving a seropositive donor
organ, CMV  syndrome/disease was reduced by approximately 43%
(10/63 to 6/65; p = 0.11) by the deployment of pre-emptive ther-
apy compared to the no therapy group while in the low risk D−R+
setting a 62% reduction (3/46 to 1/40 p = 0.8) in incidence of CMV
syndrome/disease was achieved through pre-emptive therapy. A
similar comparison for pre-emptive therapy in liver transplant
recipients could not be carried out but in the D+R+ group, receipt
of CMV  prophylaxis was  associated with a 62.5% reduction (6/75
to 2/66; p = 0.28) in CMV  syndrome/disease compared with no pro-
phylaxis. Combining both patient groups revealed that any antiviral
intervention reduced the incidence of CMV  syndrome/disease by
58% (p = 0.033).
5. DiscussionHistorically, CMV  syndrome and disease have had a major
impact on patient wellbeing after transplantation.1 However, very
few studies have attempted to quantify the impact that recent
ccording to their donor and recipient serostatus for CMV  for patients with 2 year
+ D−R− Unknown
CMV  disease (%) N CMV  disease (%) N CMV  disease (%)
4.9 178 0.6 56 3.6
2.8 104 0.0 19 0.0
0.0 18 0.0 3 33.3
18.2 31 0.0 0 0.0
19.2 19 0.0 6 0.0
9.0 350 0.1 84 7.4
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Table 4
Incidence of asymptomatic CMV  viraemia in renal transplant patients and its relationship with CMV  syndrome/disease in a subset of 4 transplant centres.
D+R−a D+R+b D−R+b D−R−
N Incidence (%) N Incidence (%) N Incidence (%) N Incidence (%)
No CMV  viraemia 37 63.8 72 66.7 42 65.6 78 96.3
Asymptomatic viraemia 7 12.1 26 24.1 21 32.8 2 2.5
CMV  syndrome 13 22.4 8 7.4 1 1.6 1 1.2
CMV  disease 1 1.7 2 1.9 0 0.0 0 0.0
a All patients received VGCV at 900 mg  od (adjusted for renal function) for 90 days.
b 2 centres used pre-emptive therapy for CMV  management.
Table 5
Incidence of asymptomatic CMV  viraemia in liver transplant patients and its relationship with CMV syndrome/disease in a subset of 3 transplant centres.
Parameter D+R−a D+R+b D+R+c D−R+
N Incidence (%) N Incidence (%) N Incidence (%) N Incidence (%)
No CMV  viraemia 37 71.2 38 79.2 48 92.3 93 94.0
Asymptomatic viraemia 4 7.7 6 12.5 3 5.8 3 3.0
CMV  syndrome 7 13.5 4 8.3 1 1.9 2 2.0
CMV  disease 4 7.7 0 0.0 0 0.0 1 1.0
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pa All 3 units used VGCV at 900 mg  od (adjusted for renal function) for 90 days.
b 2 units used no proactive CMV  management.
c Single unit using VGCV 900 mg  od (adjusted for renal function).
dvances in clinical management has had on the incidence of CMV
yndrome and disease outside of formal clinical trials. The results
f the present audit show that CMV  syndrome/disease remains an
mportant and prevalent problem following solid organ transplan-
ation in the UK. In the high risk D+R− group, the average incidence
f CMV  syndrome/disease was 20.5% consistent with previous data
or renal and liver transplant recipients receiving 90 days of val-
anciclovir prophylaxis during clinical trials.7–10 There appears to
e very few viral or immunological markers that accurately pre-
ict the subset of patients who will develop CMV  syndrome/disease
fter prophylaxis13,14 although one study has observed that T-cell
esponses at day 100 were predictive of protection against symp-
omatic infection.15 In the current study we observed that 75% and
5% of high risk renal and liver transplant recipients, respectively
ith CMV  viraemia experienced CMV  syndrome/disease arguing
hat surveillance of CMV  viraemia following prophylaxis remains
n important diagnostic. The utility of such an approach will depend
pon the sampling frequency of CMV  viraemia after the cessation of
rophylaxis16,17 as other studies have indicated that CMV  viraemia
ost prophylaxis is not a good surrogate for impending disease.18,19
he majority of centres still use prophylaxis for CMV  in high risk
atients so we believe that our audit data is an accurate reﬂection
f current practice with the caveat that some renal transplant cen-
res may  have moved to 200 days of prophylaxis based upon the
esults of the recent IMPACT study.8
Although the high-risk D+R− solid organ group is a major
oncern for the transplant team, the incidence of symptomatic
nfection in the lower risk strata should not be ignored.11,20 In
his audit, D+R+ patients had an average incidence of CMV syn-
rome/disease of 8.1% although there was signiﬁcant variation
ithin the transplant groups with the lung transplant group hav-
ng an incidence that was comparable with the D+R− group. Even
n the D−R+ setting, CMV  syndrome/disease was observed in 9.0%
f patients and was particularly prevalent in recipients of heart
nd lung transplants. Such observations argue that correct man-
gement strategies for these intermediate risk patients need to be
n place since they accounted for 58 cases of disease (51.3%) during
he study period which was comparable to 55 cases observed in the
+R− group. It was also noteworthy that in the renal transplant set-
ing pre-emptive therapy substantially reduced syndrome/disease
ompared to no therapy and in the liver transplant setting pro-
hylaxis of the D+R+ group with VGCV for 90 days had a similareffect compared to no treatment. Although this audit comprised
patients who  were transplanted 7 years ago there is little evidence
that prophylaxis has increased dramatically in this intermediate
risk group possibly reﬂecting the lack of controlled clinical trials in
this group. In addition, the incidence of CMV  viraemia in patients
being managed pre-emptively or undergoing no active manage-
ment was  comparable arguing many patients who  went on to suffer
early signs and symptoms of CMV  were in fact assessed for CMV
viraemia.
There was  only one case of CMV  disease in the D−R− group.
This group remains at very low risk of symptomatic CMV  infection
and based on our data we  would argue that this group requires no
active antiviral management outside of general clinical awareness
of the symptoms of primary CMV  infection.
In conclusion, this audit indicates that, in the UK, CMV  syn-
drome/disease remains a frequent occurrence following solid organ
transplantation and centres should endeavour to ensure that man-
agement strategies across all risk groups are robust and audited
regularly to minimise the impact of CMV  on quality of life and
ultimately graft survival.
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